Analytical Approaches in Human Sports Drug Testing - Recent Advances, Challenges, and Solutions.

Technical innovations are continuously offering new options to research and routine applications in various arenas of analytical chemistry. In combination with a concomitantly increasing knowledge in physiology and pharmacology and a steadily growing supply of new drug candidates and potential therapeutic approaches, sports drug testing laboratories have been urged to develop and refine numerous test methods and strategies in order to provide best-possible levels of information to testing authorities in support of decision-making processes in anti-doping.

[1]  M. Thevis,et al.  Peptidic drugs and drug candidates in sports drug testing: agents affecting mitochondrial biogenesis or preventing activin receptor II activation , 2019 .

[2]  A. Fragkaki,et al.  Human in vivo metabolism study of LGD-4033. , 2019, Drug testing and analysis.

[3]  M. Thevis,et al.  Studies on the in vivo metabolism of Methylstenbolone and detection of novel long term metabolites for doping control analysis. , 2019, Drug testing and analysis.

[4]  M. Nielen,et al.  Ultra-Fast Retroactive Processing of Liquid-Chromatography High-Resolution Full-Scan Orbitrap Mass Spectrometry Data in Anti-Doping Screening of Human Urine. , 2019, Rapid communications in mass spectrometry : RCM.

[5]  R. López-Arellano,et al.  Evaluation of R- (-) and S- (+) Clenbuterol enantiomers during a doping cycle or continuous ingestion of contaminated meat using chiral liquid chromatography by LC-TQ-MS. , 2019, Drug testing and analysis.

[6]  R. Bro,et al.  Multivariate Interpretation of the Urinary Steroid Profile and Training-Induced Modifications. The Case Study of a Marathon Runner. , 2019, Drug testing and analysis.

[7]  Nathalie A. Desrosiers,et al.  Oral Fluid Drug Testing: Analytical Approaches, Issues and Interpretation of Results. , 2019, Journal of analytical toxicology.

[8]  P. Cohen,et al.  The mitochondrial‐derived peptide MOTS‐c is a regulator of plasma metabolites and enhances insulin sensitivity , 2019, Physiological reports.

[9]  M. Thevis,et al.  Development of two complementary LC-HRMS methods for analyzing sotatercept in dried blood spots for doping controls. , 2019, Bioanalysis.

[10]  M. Teramoto,et al.  Assessing serum albumin concentration following exercise-induced fluid shifts in the context of the athlete biological passport. , 2019, Drug testing and analysis.

[11]  K. Kowalczyk,et al.  The use of a valid and straightforward method for the identification of higenamine in dietary supplements in view of anti-doping rule violation cases. , 2019, Drug testing and analysis.

[12]  N. Robinson,et al.  Standardization of reticulocyte counts in the athlete biological passport , 2019, International journal of laboratory hematology.

[13]  M. Nangaku,et al.  Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial , 2019, Nephron.

[14]  F. Shaikh,et al.  Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study , 2019, American Journal of Nephrology.

[15]  H. Kagechika,et al.  Androgen receptor modulators: a review of recent patents and reports (2012-2018) , 2019, Expert opinion on therapeutic patents.

[16]  Tetsuhiro Tanaka,et al.  Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet , 2019, Laboratory Investigation.

[17]  I. Grant,et al.  Validation of a liquid chromatography-tandem mass spectrometry method for analyzing cannabinoids in oral fluid. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[18]  T. Sobolevsky,et al.  Urinary concentrations of AICAR and mannitol in athlete population. , 2019, Drug testing and analysis.

[19]  D. Böhning,et al.  Exact statistical calculation of the uncertainty term in the decision limits of the GH-2000 score for growth hormone misuse (doping) detection , 2019, Statistical methods in medical research.

[20]  X. de la Torre,et al.  Isotope ratio mass spectrometry in antidoping analysis: The use of endogenous reference compounds. , 2019, Rapid communications in mass spectrometry : RCM.

[21]  Sohita Dhillon.  Roxadustat: First Global Approval , 2019, Drugs.

[22]  P. Cohen,et al.  MOTS-c: an equal opportunity insulin sensitizer , 2019, Journal of Molecular Medicine.

[23]  M. Nangaku,et al.  A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial , 2019, American Journal of Nephrology.

[24]  M. Thevis,et al.  Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes. , 2019, Rapid communications in mass spectrometry : RCM.

[25]  T. Yanase,et al.  Selective androgen receptor modulator, S42 has anabolic and anti-catabolic effects on cultured myotubes , 2019, Biochemistry and biophysics reports.

[26]  L. Lipshultz,et al.  Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. , 2019, Sexual medicine reviews.

[27]  M. Fuentes-Ferrer,et al.  Impact of the UGT2B17 polymorphism on the steroid profile. Results of a crossover clinical trial in athletes submitted to testosterone administration , 2019, Steroids.

[28]  J. Springer,et al.  Skeletal muscle wasting in chronic heart failure , 2018, ESC heart failure.

[29]  P. Van Eenoo,et al.  Development and validation of an open screening method for doping substances in urine by gas chromatography quadrupole time-of-flight mass spectrometry. , 2018, Analytica chimica acta.

[30]  M. Thevis,et al.  SARCOSYL-PAGE: Optimized Protocols for the Separation and Immunological Detection of PEGylated Proteins. , 2018, Methods in molecular biology.

[31]  M. Nielen,et al.  Comparison of gas chromatography/quadrupole time-of-flight and quadrupole Orbitrap mass spectrometry in anti-doping analysis: I. Detection of anabolic-androgenic steroids. , 2018, Rapid communications in mass spectrometry : RCM.

[32]  J. Naud,et al.  Detection of erythropoiesis stimulating agents in urine samples using a capillary Western system. , 2018, Drug testing and analysis.

[33]  M. Thevis,et al.  Recent improvements in sports drug testing concerning the initial testing for peptidic drugs (< 2 kDa) - sample preparation, mass spectrometric detection, and data review. , 2018, Drug testing and analysis.

[34]  A. Brailsford,et al.  IRMS delta values (13 C) of nandrolone and testosterone products available in the UK: Implications for anti-doping. , 2018, Drug testing and analysis.

[35]  M. Thevis,et al.  Analysis of insulin and insulin analogs from dried blood spots by means of liquid chromatography-high resolution mass spectrometry. , 2018, Drug testing and analysis.

[36]  M. Thevis,et al.  Studies on the in vivo metabolism of the SARM YK11: Identification and characterization of metabolites potentially useful for doping controls. , 2018, Drug testing and analysis.

[37]  A. Casilli,et al.  Development and validation of a multidimensional gas chromatography/combustion/isotope ratio mass spectrometry-based test method for analyzing urinary steroids in doping controls. , 2018, Analytica chimica acta.

[38]  Sota Kato,et al.  TP0463518, a novel inhibitor for hypoxia‐inducible factor prolyl hydroxylases, increases erythropoietin in rodents and monkeys with a good pharmacokinetics‐pharmacodynamics correlation , 2018, European journal of pharmacology.

[39]  M. Thevis,et al.  Combined detection of the ActRII-Fc fusion proteins Sotatercept (ActRIIA-Fc) and Luspatercept (modified ActRIIB-Fc) in serum by means of immunoaffinity purification, tryptic digestion, and LC-MS/MS. , 2018, Drug testing and analysis.

[40]  F. Hülsemann,et al.  Case Study: Atypical δ13 C values of urinary norandrosterone. , 2018, Drug testing and analysis.

[41]  D. Favretto,et al.  Multiple incidence of the prescription diuretic hydrochlorothiazide in compounded nutritional supplements. , 2018, Drug testing and analysis.

[42]  R. Pacifici,et al.  Determination of cannabinoids in oral fluid and urine of “light cannabis” consumers: a pilot study , 2018, Clinical chemistry and laboratory medicine.

[43]  S. Kageyama,et al.  Lomerizine, trimetazidine and bis-(4-fluorophenyl)-methylpiperazine in human urine after oral administration of lomerizine dihydrochloride: analysis by liquid chromatography-high resolution-tandem mass spectrometry. , 2018, Drug testing and analysis.

[44]  M. Thevis,et al.  Updated protocols for the detection of Sotatercept and Luspatercept in human serum. , 2018, Drug testing and analysis.

[45]  M. Thevis,et al.  Effects of 3 Weeks of Oral Low-Dose Cobalt on Hemoglobin Mass and Aerobic Performance , 2018, Front. Physiol..

[46]  K. Linnet,et al.  Glycine-modified growth hormone secretagogues identified in seized doping material. , 2018, Drug testing and analysis.

[47]  M. Thevis,et al.  Erythropoietic effects of low-dose cobalt application. , 2018, Drug testing and analysis.

[48]  B. Venhuis,et al.  The stimulant higenamine in weight loss and sports supplements , 2018, Clinical toxicology.

[49]  A. Marchand,et al.  Combined immuno-purification and detection of recombinant erythropoietins and activin receptor type II-Fc fusion proteins by isoelectric focusing for application in doping control. , 2018, Drug testing and analysis.

[50]  M. Popławska,et al.  Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP-2) in a seized injection vial. , 2018, Drug testing and analysis.

[51]  M. Thevis,et al.  Unambiguous identification and characterization of a long-term human metabolite of dehydrochloromethyltestosterone. , 2018, Drug testing and analysis.

[52]  A. Sickmann,et al.  Analysis of new growth promoting black market products. , 2018, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[53]  Silvia Montagna,et al.  A Bayesian Approach for the Use of Athlete Performance Data Within Anti-doping , 2018, Front. Physiol..

[54]  P. Kintz,et al.  First identification of a diuretic, hydrochlorothiazide, in hair: Application to a doping case and interpretation of the results. , 2018, Drug testing and analysis.

[55]  F. Locatelli,et al.  Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease , 2018, Expert opinion on investigational drugs.

[56]  L. Ekström,et al.  Pregnancy greatly affects the steroidal module of the Athlete Biological Passport. , 2018, Drug testing and analysis.

[57]  B. Dawson,et al.  Validation of a blood marker for plasma volume in endurance athletes during a live-high train-low altitude training camp. , 2018, Drug testing and analysis.

[58]  G. Wensing,et al.  First‐in‐man–proof of concept study with molidustat: a novel selective oral HIF‐prolyl hydroxylase inhibitor for the treatment of renal anaemia , 2018, British journal of clinical pharmacology.

[59]  B. Dawson,et al.  The need for an alternative method to determine intravascular volumes , 2018, European journal of sport science.

[60]  M. Thevis,et al.  Growth hormone isoform-differential mass spectrometry for doping control purposes. , 2018, Drug testing and analysis.

[61]  K. Kowalczyk,et al.  Analysis for higenamine in urine by means of ultra-high-performance liquid chromatography-tandem mass spectrometry: Interpretation of results. , 2018, Drug testing and analysis.

[62]  X. de la Torre,et al.  Combined chemical and biotechnological production of 20βOH-NorDHCMT, a long-term metabolite of Oral-Turinabol (DHCMT). , 2018, Journal of inorganic biochemistry.

[63]  M. Thevis,et al.  Detection of Sotatercept (ACE-011) in human serum by SAR-PAGE and western single blotting. , 2018, Drug testing and analysis.

[64]  M. Thevis,et al.  Detection of the Human Anti‐ActRII Antibody Bimagrumab in Serum by Means of Affinity Purification, Tryptic Digestion, and LC‐HRMS , 2018, Proteomics. Clinical applications.

[65]  Ó. Pozo,et al.  Evaluation of markers out of the steroid profile for the screening of testosterone misuse. Part I: Transdermal administration. , 2018, Drug testing and analysis.

[66]  J. Schulze,et al.  Sensitivity of doping biomarkers after administration of a single dose testosterone gel. , 2018, Drug testing and analysis.

[67]  Mukul R Jain,et al.  Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. , 2018, Journal of medicinal chemistry.

[68]  G. Chertow,et al.  Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[69]  M. Parkin,et al.  Peptide selection for the quantification of P-III-NP in human serum by mass spectrometry. , 2018, Rapid communications in mass spectrometry : RCM.

[70]  J. Keldenich,et al.  Discovery of Molidustat (BAY 85‐3934): A Small‐Molecule Oral HIF‐Prolyl Hydroxylase (HIF‐PH) Inhibitor for the Treatment of Renal Anemia , 2018, ChemMedChem.

[71]  I. Zvereva,et al.  Determination of GnRH and its synthetic analogues' abuse in doping control: Small bioactive peptide UPLC-MS/MS method extension by addition of in vitro and in vivo metabolism data; evaluation of LH and steroid profile parameter fluctuations as suitable biomarkers. , 2018, Drug testing and analysis.

[72]  A. Govus,et al.  Influence of combined iron supplementation and simulated hypoxia on the haematological module of the athlete biological passport. , 2018, Drug testing and analysis.

[73]  Stephane Bermon,et al.  Application of the Athlete's Performance Passport for Doping Control: A Case Report , 2018, Front. Physiol..

[74]  J. Galgani,et al.  Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals , 2018, Journal of Investigative Medicine.

[75]  Pierre-Edouard Sottas,et al.  Athlete Performance Monitoring in Anti-Doping , 2018, Front. Physiol..

[76]  P. Horvatovich,et al.  High resolution full scan liquid chromatography mass spectrometry comprehensive screening in sports antidoping urine analysis , 2018, Journal of pharmaceutical and biomedical analysis.

[77]  K. Nemoto,et al.  Selective Androgen Receptor Modulator, YK11, Up-Regulates Osteoblastic Proliferation and Differentiation in MC3T3-E1 Cells. , 2018, Biological & pharmaceutical bulletin.

[78]  Lucas Martins Lisandro Rodrigues,et al.  Non-targeted acquisition strategy for screening doping compounds based on GC-EI-hybrid quadrupole-Orbitrap mass spectrometry: A focus on exogenous anabolic steroids. , 2018, Drug testing and analysis.

[79]  L. Engebretsen,et al.  IOC consensus statement: dietary supplements and the high-performance athlete , 2018, British Journal of Sports Medicine.

[80]  Norbert Baume,et al.  Analytical challenges in sports drug testing , 2018, Analytical and Bioanalytical Chemistry.

[81]  A. Donovan,et al.  Blocking extracellular activation of myostatin as a strategy for treating muscle wasting , 2018, Scientific Reports.

[82]  D. Volmer,et al.  Mass spectrometric studies on selective androgen receptor modulators (SARMs) using electron ionization and electrospray ionization/collision-induced dissociation , 2018, European journal of mass spectrometry.

[83]  O. Beck,et al.  A liquid chromatography and tandem mass spectrometry method to determine 28 non‐volatile drugs of abuse in exhaled breath , 2018, Journal of pharmaceutical and biomedical analysis.

[84]  Sergei Iljukov,et al.  Performance Profiling—Perspectives for Anti-doping and beyond , 2017, Front. Physiol..

[85]  M. Pappalardi,et al.  Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor–Prolyl Hydroxylase Inhibitor for Anemia , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[86]  M. Vukasinović-Vesić,et al.  Determination of higenamine in dietary supplements by UHPLC/MS/MS method , 2017, Journal of pharmaceutical and biomedical analysis.

[87]  P. Deuster,et al.  Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet , 2017, JAMA.

[88]  K. Fukui,et al.  Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia. , 2017, ACS medicinal chemistry letters.

[89]  Chris R. Abbiss,et al.  Considerations on the Assessment and Use of Cycling Performance Metrics and their Integration in the Athlete's Biological Passport , 2017, Front. Physiol..

[90]  C. Buisson,et al.  Implementation of AICAR analysis by GC-C-IRMS for anti-doping purposes. , 2017, Drug testing and analysis.

[91]  J. Naud,et al.  Immunomagnetic beads-based isolation of erythropoietins from urine and blood for sports anti-doping control. , 2017, Drug testing and analysis.

[92]  K. Deventer,et al.  Identification and characterization of novel long-term metabolites of oxymesterone and mesterolone in human urine by application of selected reaction monitoring GC-CI-MS/MS. , 2017, Drug testing and analysis.

[93]  M. Thevis,et al.  Epiandrosterone sulfate prolongs the detectability of testosterone, 4-androstenedione, and dihydrotestosterone misuse by means of carbon isotope ratio mass spectrometry. , 2017, Drug testing and analysis.

[94]  M. Thevis,et al.  lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls. , 2017, Drug testing and analysis.

[95]  S. Kageyama,et al.  Determination of higenamine and coclaurine levels in human urine after the administration of a throat lozenge containing Nandina domestica fruit. , 2017, Drug testing and analysis.

[96]  X. de la Torre,et al.  Fast IRMS screening of pseudoendogenous steroids in doping analyses. , 2017, Drug testing and analysis.

[97]  Á. Gil-Izquierdo,et al.  Intended or Unintended Doping? A Review of the Presence of Doping Substances in Dietary Supplements Used in Sports , 2017, Nutrients.

[98]  J. Dalton.  The long and winding road for selective androgen receptor modulators. , 2017, British journal of clinical pharmacology.

[99]  C. Gore,et al.  Temporal changes in physiology and haematology in response to high- and micro-doses of recombinant human erythropoietin. , 2017, Drug testing and analysis.

[100]  M. Thevis,et al.  Characterization of in vitro generated metabolites of selected peptides <2 kDa prohibited in sports. , 2017, Drug testing and analysis.

[101]  M. Thevis,et al.  Antibody-based strategies for the detection of Luspatercept (ACE-536) in human serum. , 2017, Drug testing and analysis.

[102]  M. Nielen,et al.  Gas chromatographic quadrupole time-of-flight full scan high resolution mass spectrometric screening of human urine in antidoping analysis. , 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[103]  Neilson M Mathews.  Prohibited Contaminants in Dietary Supplements , 2017, Sports health.

[104]  M. Thevis,et al.  Immunoaffinity techniques coupled to mass spectrometry for the analysis of human peptide hormones: advances and applications , 2017, Expert review of proteomics.

[105]  M. Thevis,et al.  Mass spectrometric characterization of the selective androgen receptor modulator (SARM) YK-11 for doping control purposes. , 2017, Rapid communications in mass spectrometry : RCM.

[106]  M. Thevis,et al.  Expanding analytical options in sports drug testing: Mass spectrometric detection of prohibited substances in exhaled breath , 2017, Rapid communications in mass spectrometry : RCM.

[107]  N. Robinson,et al.  Hepcidin as a potential biomarker for blood doping. , 2017, Drug testing and analysis.

[108]  R. Ventura,et al.  Detection of stanozolol O- and N-sulfate metabolites and their evaluation as additional markers in doping control. , 2017, Drug testing and analysis.

[109]  J. Dalton,et al.  Development of selective androgen receptor modulators (SARMs) , 2017, Molecular and Cellular Endocrinology.

[110]  Jose M Garcia,et al.  Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects , 2017, Molecular and Cellular Endocrinology.

[111]  J. Wish,et al.  Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[112]  H. Patel,et al.  Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers , 2017, Clinical Pharmacokinetics.

[113]  H. Patel,et al.  A sensitive assay for ZYAN1 in human whole blood and urine utilizing positive LC-MS/MS electrospray ionization. , 2017, Bioanalysis.

[114]  D. H. Strand,et al.  Determination of 21 drugs in oral fluid using fully automated supported liquid extraction and UHPLC-MS/MS. , 2017, Drug testing and analysis.

[115]  A. Murphy,et al.  Activin A more prominently regulates muscle mass in primates than does GDF8 , 2017, Nature Communications.

[116]  M. Parr,et al.  Distinction of clenbuterol intake from drug or contaminated food of animal origin in a controlled administration trial – the potential of enantiomeric separation for doping control analysis , 2017, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment.

[117]  V. Haase,et al.  HIF‐prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism , 2017, Hemodialysis international. International Symposium on Home Hemodialysis.

[118]  M. Thevis,et al.  Investigation of the metabolites of the HIF stabilizer FG‐4592 (roxadustat) in five different in vitro models and in a human doping control sample using high resolution mass spectrometry , 2017, Journal of pharmaceutical and biomedical analysis.

[119]  Ó. Pozo,et al.  In vitro metabolism study of a black market product containing SARM LGD-4033. , 2017, Drug testing and analysis.

[120]  Ó. Pozo,et al.  Evaluation of two glucuronides resistant to enzymatic hydrolysis as markers of testosterone oral administration , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[121]  M. Thevis,et al.  Detection of SARMs in doping control analysis , 2017, Molecular and Cellular Endocrinology.

[122]  M. Saugy,et al.  Erythropoietin as a performance-enhancing drug: Its mechanistic basis, detection, and potential adverse effects , 2017, Molecular and Cellular Endocrinology.

[123]  P. Sottas,et al.  The use of biomarkers to describe plasma‐, red cell‐, and blood volume from a simple blood test , 2017, American journal of hematology.

[124]  M. Thevis,et al.  Simplifying and expanding analytical capabilities for various classes of doping agents by means of direct urine injection high performance liquid chromatography high resolution/high accuracy mass spectrometry. , 2016, Journal of pharmaceutical and biomedical analysis.

[125]  V. Haase,et al.  Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. , 2016, Kidney international.

[126]  P. Gärtner,et al.  Synthesis of 17β-hydroxymethyl-17α-methyl-18-norandrosta-1,4,13-trien-3-one: A long-term metandienone metabolite , 2016, Steroids.

[127]  A. Casilli,et al.  Optimization of an online heart-cutting multidimensional gas chromatography clean-up step for isotopic ratio mass spectrometry and simultaneous quadrupole mass spectrometry measurements of endogenous anabolic steroid in urine. , 2016, Drug testing and analysis.

[128]  X. de la Torre,et al.  Longitudinal evaluation of the isotope ratio mass spectrometric data: towards the 'isotopic module' of the athlete biological passport? , 2016, Drug testing and analysis.

[129]  Wilhelm Schänzer,et al.  Sports drug testing using complementary matrices: Advantages and limitations. , 2016, Journal of pharmaceutical and biomedical analysis.

[130]  G. Rodchenkov,et al.  Comparison of various in vitro model systems of the metabolism of synthetic doping peptides: Proteolytic enzymes, human blood serum, liver and kidney microsomes and liver S9 fraction. , 2016, Journal of proteomics.

[131]  N. Nordsborg,et al.  Detection of erythropoietin misuse by the Athlete Biological Passport combined with reticulocyte percentage. , 2016, Drug testing and analysis.

[132]  M. Thevis,et al.  Detection of the diuretic hydrochlorothiazide in a doping control urine sample as the result of a non-steroidal anti-inflammatory drug (NSAID) tablet contamination. , 2016, Forensic science international.

[133]  G. Rodchenkov,et al.  Solid-phase extraction of small biologically active peptides on cartridges and microelution 96-well plates from human urine. , 2016, Drug testing and analysis.

[134]  A. Verstraete,et al.  Δ(9)-Tetrahydrocannabinol concentrations in exhaled breath and physiological effects following cannabis intake - A pilot study using illicit cannabis. , 2016, Clinical biochemistry.

[135]  S. Rzeppa,et al.  Analysis of sulfate metabolites of the doping agents oxandrolone and danazol using high performance liquid chromatography coupled to tandem mass spectrometry. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[136]  M. Thevis,et al.  Revisiting the metabolism of 19-nortestosterone using isotope ratio and high resolution/high accuracy mass spectrometry , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[137]  M. Thevis,et al.  Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls. , 2016, Drug testing and analysis.

[138]  M. Thevis,et al.  Analytical detection of trimetazidine produced by metabolic conversion of lomerizine in doping control analysis. , 2016, Drug testing and analysis.

[139]  M. Saugy,et al.  Autologous Blood Transfusion in Sports: Emerging Biomarkers. , 2016, Transfusion medicine reviews.

[140]  K. Deventer,et al.  Efficient approach for the detection and identification of new androgenic metabolites by applying SRM GC-CI-MS/MS: a methandienone case study. , 2016, Journal of mass spectrometry : JMS.

[141]  R. Holt,et al.  Growth Hormone and Insulin-Like Growth Factor-1. , 2016, Frontiers of hormone research.

[142]  M. Sahay,et al.  A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[143]  Ó. Pozo,et al.  Detection and characterization of clostebol sulfate metabolites in Caucasian population. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[144]  E. Alladio,et al.  Application of multivariate statistics to the Steroidal Module of the Athlete Biological Passport: A proof of concept study. , 2016, Analytica chimica acta.

[145]  L. Mercolini,et al.  LC-MS/MS and volumetric absorptive microsampling for quantitative bioanalysis of cathinone analogues in dried urine, plasma and oral fluid samples. , 2016, Journal of pharmaceutical and biomedical analysis.

[146]  N. Robinson,et al.  Hepcidin as a new biomarker for detecting autologous blood transfusion , 2016, American journal of hematology.

[147]  Sheng Yang,et al.  New drostanolone metabolites in human urine by liquid chromatography time-of-flight tandem mass spectrometry and their application for doping control , 2016, Steroids.

[148]  M. Thevis,et al.  Identification of Selected in vitro-Generated Phase-I Metabolites of the Steroidal Selective Androgen Receptor Modulator MK-0773 for Doping Control Purposes , 2016, European journal of mass spectrometry.

[149]  C. Buisson,et al.  Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: Investigation on a positive case. , 2016, Journal of pharmaceutical and biomedical analysis.

[150]  M. Thevis,et al.  Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs. , 2016, Rapid communications in mass spectrometry : RCM.

[151]  Å. Øiestad,et al.  Oral fluid drug analysis in the age of new psychoactive substances. , 2016, Bioanalysis.

[152]  K. Deventer,et al.  Gas chromatography/chemical ionization triple quadrupole mass spectrometry analysis of anabolic steroids: ionization and collision-induced dissociation behavior. , 2016, Rapid communications in mass spectrometry : RCM.

[153]  R. Ventura,et al.  Bioanalytical techniques in discrimination between therapeutic and abusive use of drugs in sport. , 2016, Bioanalysis.

[154]  M. Dohi,et al.  Comparison of urine analysis and dried blood spot analysis for the detection of ephedrine and methylephedrine in doping control. , 2016, Drug testing and analysis.

[155]  C. Evans,et al.  Overcoming bioanalytical challenges associated with the separation and quantitation of GSK1278863, a HIF-prolyl hydroxylase inhibitor, and its 14 stereoisomeric metabolites. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[156]  M. Thevis,et al.  Solutions Advertised as Erythropoiesis-stimulating Products were Found to Contain Undeclared Cobalt and Nickel Species , 2016, International Journal of Sports Medicine.

[157]  M. Thevis,et al.  Formation of the diuretic chlorazanil from the antimalarial drug proguanil--implications for sports drug testing. , 2015, Journal of pharmaceutical and biomedical analysis.

[158]  N. Ntoumanis,et al.  What if it really was an accident? The psychology of unintentional doping , 2015, British Journal of Sports Medicine.

[159]  Changhan Lee,et al.  The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. , 2015, Cell metabolism.

[160]  A. Vernec.  The Athlete Biological Passport: an integral element of innovative strategies in antidoping , 2014, British Journal of Sports Medicine.

[161]  M. Thevis,et al.  Expanding analytical possibilities concerning the detection of stanozolol misuse by means of high resolution/high accuracy mass spectrometric detection of stanozolol glucuronides in human sports drug testing. , 2013, Drug testing and analysis.

[162]  M. Thevis,et al.  Synthesis, characterization, and detection of new oxandrolone metabolites as long-term markers in sports drug testing , 2013, Analytical and Bioanalytical Chemistry.

[163]  M. Bidlingmaier.  New detection methods of growth hormone and growth factors. , 2012, Endocrine development.

[164]  T. Sobolevsky,et al.  Mass spectrometric description of novel oxymetholone and desoxymethyltestosterone metabolites identified in human urine and their importance for doping control. , 2012, Drug testing and analysis.

[165]  T. Sobolevsky,et al.  Detection and mass spectrometric characterization of novel long-term dehydrochloromethyltestosterone metabolites in human urine , 2012, The Journal of Steroid Biochemistry and Molecular Biology.

[166]  M. Thevis,et al.  Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine. , 2006, Rapid communications in mass spectrometry : RCM.

[167]  Sanjay K. Jain,et al.  Effective and controlled transdermal delivery of ephedrine , 1990 .

[168]  J. Franck,et al.  Drug abuse screening with exhaled breath and oral fluid in adults with substance use disorder. , 2019, Drug testing and analysis.

[169]  A. Marchand,et al.  Detection of Hypoxia-Regulated MicroRNAs in Blood as Potential Biomarkers of HIF Stabilizer Molidustat. , 2019, MicroRNA.

[170]  L. Lerman,et al.  Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. , 2018, International journal of cardiology.

[171]  Ó. Pozo,et al.  Evaluation of markers out of the steroid profile for the screening of testosterone misuse. Part II: Intramuscular administration. , 2018, Drug testing and analysis.

[172]  M. Thevis,et al.  Human sports drug testing by mass spectrometry. , 2017, Mass spectrometry reviews.

[173]  Zhe Wang,et al.  A novel HPLC-MRM strategy to discover unknown and long-term metabolites of stanozolol for expanding analytical possibilities in doping-control. , 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[174]  N. Robinson,et al.  The Athlete Biological Passport: How to Personalize Anti-Doping Testing across an Athlete's Career? , 2017, Medicine and sport science.

[175]  M. Thevis,et al.  Applications of Isotope Ratio Mass Spectrometry in Sports Drug Testing Accounting for Isotope Fractionation in Analysis of Biological Samples. , 2017, Methods in enzymology.

[176]  J. Segura,et al.  Structure-activity relationship for peptídic growth hormone secretagogues. , 2017, Drug testing and analysis.

[177]  D. Eichner,et al.  Detection of LGD-4033 and its metabolites in athlete urine samples. , 2017, Drug testing and analysis.

[178]  M. Thevis,et al.  Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls. , 2017, Drug testing and analysis.

[179]  M. Thevis,et al.  Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry. , 2016, Journal of separation science.

[180]  M. Thevis,et al.  Simultaneous determination of insulin, DesB30 insulin, proinsulin, and C-peptide in human plasma samples by liquid chromatography coupled to high resolution mass spectrometry , 2016, Forensic Toxicology.

[181]  J. Henion,et al.  Quantitative determination of opioids in whole blood using fully automated dried blood spot desorption coupled to on-line SPE-LC-MS/MS. , 2016, Drug testing and analysis.